Ispecimen Inc. · NASDAQ:ISPC
Ispecimen — IPO Roadshow (May 2021)
31 slides from Ispecimen's IPO roadshow presentation, May 28, 2021
Slide 1: Transforming Biospecimen Procurement
CONNECT. INNOVATE. JUNE 2021 Investor Presentation TRANSFORMING BIOSPECIMEN PROCUREMENT An online marketplace for human biospecimens
Slide 2: Forward Looking Statements
The securities of iSpecimen Inc . ("iSpecimen," "we," "us," "our" or the "Company") may only be sold pursuant to an effective registration statement filed with the Securities and Exchange Commission (the "SEC") or an exemption therefrom . The information provided herein is provided to you on the con
Slide 3: Registration statement and offering notice
We have filed a registration statement (including a preliminary prospectus) with the SEC for the offering to which this presentation relates . The registration statement has not yet become effective . Before you invest, you should read the preliminary prospectus in the registration statement (includ
Slide 4: Offering Summary
Offering Summary ISSUER iSpecimen Inc . PROPOSED AGGREGATE OFFERING $20,000,000 PRICE RANGE $8.00 - $10.00 PROPOSED EXCHANGE / SYMBOL NASDAQ / ISPC COMMON SHARES OFFERED 2,222,222 PRE - IPO COMMON SHARES OUTSTANDING 4,018,129 OVER - ALLOTMENT OPTION 15% USE OF PROCEEDS Further development of technol
Slide 5: Christopher Ianelli, MD PhD, Chief Executive Officer
Christopher Ianelli, MD PhD | Chief Executive Officer, President, and Director Dr . Ianelli has been serving as our Chief Executive Officer, President, and Director since founding iSpecimen in July 2009 . Dr . Ianelli served as Chief Executive Officer of Abkine Pharmaceuticals, Inc . Dr . Ianelli se
Slide 6: Investment Highlights
Investment Highlights 6 180+ Healthcare Provider / Supplier Organizations ~350 Customers Organizations 1. Early - stage opportunity with a first mover advantage 2. $3B - $4B global biospecimen market growing at 10 - 15% per year 1 3. Unique two - sided marketplace disrupting the biospecimen procurem
Slide 7: Our Vision
Accelerate scientific discovery in an online marketplace that empowers researchers to instantly search for and gain access to patients, biospecimens, and data across a global network of healthcare providers Our Vision 7
Slide 8: Human Biospecimens are Essential for Life Science R&D
Human Biospecimens are Essential for Life Science R&D Basic Research Biomarker ID & Validation Drug Discovery & Development Diagnostics Discovery & Validation Biofluids Solid Tissue Stem & Immune Cells Plasm, Serum, Urine, Saliva Industry Academia Government 8 Lung, Breast, Colon, Brain Bone Marrow,
Slide 9: Large and Inefficient Biospecimen Market
10 - 15% Annual Growth Fueled by precision and regenerative medicine research 2 Disconnected Market Participants in Need of a Marketplace Solution With an Inefficient Supply Chain Manual processes plus fragmentation make it ripe for an online marketplace solution Large and Inefficient Biospecimen Ma
Slide 10: Market Inefficiencies
Market Inefficiencies PROVIDER RESEARCHER Scientist / Informaticist Procurement Legal Compliance IT / Informaticist Scientist Informaticist Legal Compliance IT / Informaticist Researcher Procurement Legal Compliance Principal Investigator Specimen Operations PATIENTS PROVIDERS RESEARCHERS 10
Slide 11: Inefficiencies Lead to Losses
Inefficiencies Lead to Losses Providers miss revenue and research opportunities > 3 Billion clinical specimens are discarded annually worldwide 5 > 1 Billion Patient encounters yearly in the U.S. where a specimen could be provided for research 4 > 800 Million banked specimens are in biorepository in
Slide 12: The iSpecimen Marketplace Solution
The iSpecimen Marketplace Solution 12 PROVIDER Procurement Principal Investigator / Operations IT / Informaticist PATIENTS Legal & Compliance IT / Informaticist Researcher & Procurement Legal & Compliance Principal Investigator & Specimen Operations Scientist & Informaticist Blood / Pheresi s Center
Slide 13: Full-Service Procurement
Full-Service Procurement We not only Connect Suppliers and Customers, but We also Manage the Entire Procurement Process Click to See the Overview Video SPECIMEN SEARCH SELECTION SPECIMEN LOGISTICS SPECIMEN MANAGEMENT DATA MANAGEMENT STUDY/ORDER MANAGEMENT SUPPLIER SITE TRAINING COLLECTION KIT BUILDI
Slide 14: Suppliers and Researchers Benefit
Suppliers and Researchers Benefit Advance Discovery Suppor t research mission and advance diagnostic, therapeutic, and vaccine research Increase Revenue Instantly connect to a global network of researchers Ensure Compliance On a platform that protects the privacy and security of patient information
Slide 15: Growing Supplier Adoption
13 34 66 102 147 181 189 2015 2016 2017 2018 2019 2020 March 31, 2021 Growing Supplier Adoption 700+ Hospitals Also includes three Healthcare Information Exchanges 69% CAGR Number of Suppliers (2015 - 2020) WORLDWIDE COVERAGE United States United Kingdom Germany France Ukraine Georgia Bulgaria Russi
Slide 16: Growing Researcher Adoption
43 58 559 1,332 2,271 3,241 3,510 2015 2016 2017 2018 2019 2020 March 31, 2021 Unique Customer Organizations with Purchases 2015 – March 31, 2021 69% CAGR Customers (2015 - 2020) Registered Research Users on the iSpecimen Marketplace 2015 – March 31, 2021 137% CAGR Registered Users (2015 - 2020) Gro
Slide 17: Strong Sales Pipeline
$54.3 M $76.8 M 2019 2020 Strong Sales Pipeline 41% CAGR Inquires $76.8M Inquiries FEASABILITY ASSESSMENT CUSTOMER ACCEPTANCE FULFILLMENT $64.3M Quotes $14.6M Purchase Orders $8.2M Revenue 2020 Sales Pipeline Performance 2019 - 2020 Growth in Each Stage of Sales Pipeline $36.6 M $64.3 M 2019 2020 76
Slide 18: Rich Data is Our Key Differentiator
“Utilization of sample data for research and for monetization is the next key value driver for the biobanks.” - Frost & Sullivan, Global Biobanking Market Landscape Rich Data is Our Key Differentiator Banked Specimen Records Patient Records Medical Condition Records Clinical Specimen Records Laborat
Slide 19: Statements of Operations Information
$4.3M $8.2M 2019 2020 $1.7M $3.0M March 31, 2020 March 31, 2021 Statements of Operations InformationFor the Three Months Ended March 31, For the Years Ended December 31, 2021 (unaudited) 2020 (unaudited) 2020 2019 Revenue $ 2,963,807 $ 1,711,660 $ 8,184,106 $ 4,298,350 Operating Expenses Cost of Rev
Slide 20: Balance Sheet as of March 31, 2021
As of March 31, 2021 Assets (unaudited) Cash and Cash Equivalents $ 355,126 Accounts Receivable -Unbilled 1,079,734 Accounts Receivable, Net 580,196 Due from factor 495,735 Prepaid Expenses and Other Current Assets 428,084 Tax Credit Receivable, Current Portion 179,376 Property, Plant, and Equipment
Slide 21: Pre-IPO Capitalization Table
21 Pre-IPO Capitalization TableCommon Stock* 4,018,129 Options (WAEP: $1.00) 265,102 Warrants (WAEP: $0.06) 23,309 Pro Forma Fully Diluted Common Stock Outstanding 4,306,540 *On a pro forma basis, to give effect for: o936,213 common stock outstanding o$6.7M of ConvertibleNotes and accrued interest c
Slide 22: Use of Proceeds
Objective Expand iSpecimen MarketplaceSupport more diverse and complex data sets, enhance search functionality (including patient/subject search), improve user workflows, and optimize administrative and reporting functionality $ 3,000,000 Increase Research Users Grow our sales and marketing efforts,
Slide 23: Investment Summary
Investment Summary 180+ Suppliers and ~350 Customers Organizations 150,000+ Specimens Delivered 66,000,000+ Specimen Records in the iSpecimen Marketplace 23 1. Early - stage opportunity with a first mover advantage 2. $3B - $4B global biospecimen market growing at 10 - 15% per year 1 3. Unique two -
Slide 24: Connect. Innovate. Contact Us
CONNECT. INNOVATE. Sign up for free iSpecimen Marketplace account at www.ispecimen.com Engage in a Q&A session with the executives for more information CONTACT US Chris IANELL I iSpecimen Inc. 450 Bedford Street Lexington, MA 02420 o: 781 - 301 - 6688 e: cianelli@ispecimen.com ispecimen.com
Slide 25: Appendix
Appendix QiSPECIMEN 25
Slide 26: Strategic Evolution
Strategic Evolution PHASE 3 Expansion via the Online iSpecimen Marketplace Ƞ START UP Company Ideation and Self - Funding PHASE 1 Proof of Concept PHASE 2 Critical Mass of Suppliers and Early Customer Adoption 2010 – 2011 2012 – 2013 2014 – 2017 2018 – March 31, 2021 0 Customers 1 Supplier Agreement
Slide 27: iSpecimen Marketplace UI/UX: Tissue Search Example
iSpecimen Marketplace UI/UX Use Pulldowns to Enter Three High Level Search Criteria Tissue Search Example 27
Slide 28: iSpecimen Marketplace UI/UX: View Initial Results
to View Initial Results View Case Cards to See Specimens that Meet Criteria 28 iSpecimen Marketplace UI/UX
Slide 29: iSpecimen Marketplace UI/UX: Refine Search Results
Refine Search Results Using Sliders and Check Boxes Add Specimens to the Cart iSpecimen Marketplace UI/UX 29
Slide 30: iSpecimen Marketplace UI/UX: View Cart and Request Quote
View Cart and Add More Specimens Request a Quote iSpecimen Marketplace UI/UX 30 Track and Manage Requests
Slide 31: Sources Cited
31 Page Note Source Cited 8 1 iSpecimen estimates based on In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product, By Application, By Technology (Immunochemistry, Molecular Diagnostics) By End - use, By Region, And Segment Forecasts, 2021 – 2027. Grandview Research, January 2021